Polymorphism rs7692387 of GUCY1A1 as a genetic marker for peripheral artery disease in cigarette smokers
AbstractIt is known that polymorphisms at gene encoding GUCY1A1 (α-subunit 1 of guanylate cyclase type 1) are associated with a predisposition to coronary artery disease and arterial hypertension, however, the relationship between these polymorphisms and the risk of peripheral artery disease (PAD) remains unexplored. This pilot study aimed to study the association of two polymorphisms such as rs7692387 and rs13139571 of the GUCY1A1 gene with the risk of peripheral artery disease. The study included 1277 unrelated individuals of Slavic origin, including 629 PAD patients and 648 relatively healthy volunteers. Genotyping of polymorphisms was done by the MassARRAY-4 system. We found that the rs7692387-A allele (OR=1.42, 95% CI 1.17–1.74, p=0.0005) and the rs7692387-G/A-A/A genotypes (OR=1.77, 95% CI 1.28–2.44, p=0.0005) were associated with an increased risk of peripheral artery disease, regardless of sex, age, body mass index, coronary artery disease, and hypertension. In addition, haplotype rs7692387A-rs13139571A (OR=1.52, 95%CI 1.17–1.98, p=0.002) was associated with an increased risk, while haplotype rs7692387G-rs13139571A (OR=0.26, 95%CI 0.12–0.58, p=0.0090), on the contrary, possessed a protective effect against disease risk. However, the observed associations occurred in cigarette smokers. Bioinformatics analysis showed that polymorphism rs7692387 is a functionally significant variant associated with increased GUCY1A1 expression and alternative polyadenylation in the tibial artery as well as a target for transcription factors and epigenetic regulation of gene expression. Thus, polymorphism rs7692387 of the GUCY1A1 gene represents a new genetic variant by which cigarette smoking, a major risk factor for peripheral artery disease, contributes to the disease development.
Keywords:peripheral artery disease; genetic predisposition; guanylate cyclase; GUCY1A1; single nucleotide polymorphism; cigarette smoking
Funding. The study had no financial support.
Conflict of interest. The authors declare no conflicts of interest.
Authors’ contribution. Study conception and design – Zhabin S.N., Polonikov A.V., Lazarenko V.A.; data collection and handling – Zhabin S.N., Chernousova S.S., Azarova I.E., Klyosova E.Yu., Bykanova M.A.; statistical processing – Zhabin S.N., Polonikov A.V.; draft manuscript preparation – Polonikov A.V., Zhabin S.N., Bashkatov D.A.; manuscript revision – Polonikov A.V., Bashkatov D.A.
For citation: Zhabin S.N., Lazarenko V.A., Chernousova S.S., Bashkatov D.A., Azarova I.E., Klyosova E.Yu., Bykanova M.A., Polonikov A.V. Polymorphism rs7692387 of GUCY1A1 as a genetic marker for peripheral artery disease in cigarette smokers. Angiology and Vascular Surgery. Journal named Academician A.V. Pokrovsky. 2022; 28 (2): 36–42. DOI: https://doi.org/10.33029/1027-6661-2022-28-2-36-42 (in Russian)
References
1. Kalinin R.E., Suchkov I.A., Chobanian A.A., et al. Markers of the course of obliterating atherosclerosis of lower limb arteries. Angiology and Vascular Surgery. 2021; 27 (2): 17–23. DOI: https://doi.org/10.33529/ANGIO2021203. (in Russian)
2. Zhang R., Lai Z.C., Liu C.W. Femoral-popliteal Arteriosclerosis Obliterans: Review of Evidence-based Studies on Drug-eluting Endovascular Treatment. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae. 2019; 41 (2): 256–260. DOI: https://doi.org/10.3881/j.issn.1000-503X.10849. (In Chinese)
3. Klarin D., Tsao P.S., Damrauer S.M. Genetic Determinants of Peripheral Artery Disease. Circulation Research. 2021; 128 (12): 1805–1817. DOI: https://doi.org/10.1161/CIRCRESAHA.121.318327
4. GWAS Catalog [Электронный ресурс]. URL: https://www.ebi.ac.uk/gwas/home (дата обращения 15.02.2022)
5. Wittenborn E.C., Marletta M.A. Structural Perspectives on the Mechanism of Soluble Guanylate Cyclase Activation. International Journal of Molecular Sciences. 2021; 22 (11): 5439. DOI: https://doi.org/10.3390/ijms22115439
6. Mineharu Y., Miyamoto S. RNF213 and GUCY1A3 in Moyamoya Disease: Key Regulators of Metabolism, Inflammation, and Vascular Stability. Frontiers in Neurology. 2021; 12: 687088. DOI: https://doi.org/10.3389/fneur.2021.687088
7. Kessler T., Wobst J., Wolf B., et al. Functional Characterization of the GUCY1A3 Coronary Artery Disease Risk Locus. Circulation. 2017; 136 (5): 476–489. DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.024152
8. Wallace S., Guo D.C., Regalado E., et al. Disrupted nitric oxide signaling due to GUCY1A3 mutations increases risk for moyamoya disease, achalasia and hypertension. Clinical Genetics. 2016; 90 (4): 351–360. DOI: https://doi.org/10.1111/cge.12739
9. Azarova I.E., Klyosova E.Yu., Sakali S.Yu., et al. Contribution of rs11927381 polymorphism of the IGF2BP2 gene to the pathogenesis of type 2 diabetes. Research Results in Biomedicine. 2020; 6 (1): 9–19. DOI: https://doi.org/10.18413/2658-6533-2020-6-1-0-2. (in Russian)
10. Van der Harst P., Verweij N. Identification of 64 Novel Genetic Loci Provides an Expanded View on the Genetic Architecture of Coronary Artery Disease. Circulation Research. 2018; 122 (3): 433–443. DOI: https://doi.org/10.1161/CIRCRESAHA.117.312086
11. Sung Y.J., Winkler T.W., de Las Fuentes L., et al. A Large-Scale Multi-ancestry Genome-wide Study Accounting for Smoking Behavior Identifies Multiple Significant Loci for Blood Pressure. American Journal of Human Genetics. 2018; 102 (3): 375–400. DOI: https://doi.org/10.1016/ j.ajhg.2018.01.015
12. Ensembl Genome Browser [Электронный ресурс]. URL: http://grch37.ensembl.org/index.html (дата обращения 15.02.2022)
13. GTEx Portal [Электронный ресурс]. URL: https://gtexportal.org/home (дата обращения 15.02.2022)
14. Segura-Puimedon M., Mergia E., Al-Hasani J., et al. Proatherosclerotic Effect of the α1-Subunit of Soluble Guanylyl Cyclase by Promoting Smooth Muscle Phenotypic Switching. American Journal of Pathology. 2016; 186 (8): 2220–2231. DOI: https://doi.org/10.1016/j.ajpath. 2016.04.010
15. Hall K.T., Kessler T., Buring J.E., et al. Genetic variation at the coronary artery disease risk locus GUCY1A3 modifies cardiovascular disease prevention effects of aspirin. European Heart Journal. 2019; 40 (41): 3385–3392. DOI: https://doi.org/10.1093/eurheartj/ehz384
16. Nording H., Baron L., Langer H.F. Platelets as therapeutic targets to prevent atherosclerosis. Atherosclerosis. 2020; 307: 97–108. DOI: https://doi.org/10.1016/j.atherosclerosis.2020.05.018
17. Hervé D., Philippi A., Belbouab R., et al. Loss of α1β1 soluble guanylate cyclase, the major nitric oxide receptor, leads to moyamoya and achalasia. American Journal of Human Genetics. 2014; 94 (3): 385–94. DOI: https://doi.org/10.1016/j.ajhg.2014.01.018
18. Ambrose J.A., Barua R.S. The pathophysiology of cigarette smoking and cardiovascular disease: an update. Journal of the American College of Cardiology. 2004; 43 (10): 1731–1737. DOI: https://doi.org/10.1016/j.jacc.2003.12.047
19. Wang W., Zhao T., Geng K., et al. Smoking and the Pathophysiology of Peripheral Artery Disease. Frontiers in Cardiovascular Medicine. 2021; 8: 704106. DOI: https://doi.org/10.3389/fcvm.2021.704106
20. GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 2015; 348 (6235): 648–660. DOI: https://doi.org/10.1126/science.1262110
21. Di Giammartino D.C., Nishida K., Manley J.L. Mechanisms and consequences of alternative polyadenylation. Molecular Cell. 2011; 43 (6): 853–866. DOI: https://doi.org/10.1016/j.molcel.2011.08.017
22. Jiang C.L., He S.W., Zhang Y.D., et al. Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017; 8 (1): 1369–1391. DOI: https://doi.org/10.18632/oncotarget.13622
23. Xiong R., Wu Y., Wu Q., et al. Integration of transcriptome analysis with pathophysiological endpoints to evaluate cigarette smoke toxicity in an in vitro human airway tissue model. Archives of Toxicology. 2021; 95 (5): 1739–1761. DOI: https://doi.org/10.1007/s00204-021-03008-0